Stephen Kaldor, Ph.D. is Co-Founder and CEO of the Fount Therapeutics group of companies. Steve is a seasoned biotech and pharmaceutical industry executive with over 25 years of experience in creating meaningful medicines and shareholder value. He served as CEO of Quanticel, a cancer drug discovery biotech that was acquired by Celgene in 2015 for $485M. Steve has contributed to other companies including Syrrx (President & CSO, 2005 $270M acquisition by Takeda), Amira (Independent Board Member, 2011 $475M acquisition by BMS), Ambrx (CEO & President), Furiex (NASDAQ: FURX, Independent Board Member, 2014 $1.46B acquisition by Forest/Actavis), and Crinetics (NASDAQ: CRNX, current Independent Board Member). He is a co-inventor of three marketed drugs (Viracept®; Nesina®; Zafatek®) plus multiple other compounds currently in clinical trials. Steve started his career at Lilly in 1990 and is a chemist by training (Columbia B.A.; Harvard Ph.D.).